Taxol vs. Abraxane in recurrent IBC?

Save as Favorite
Sign in to receive recommendations (Learn more)
Question from Barb: Can you comment on the use of Taxol vs. Abraxane in the treatment of recurrence in IBC, especially for the triple-negative cases?
Answers - Gabriel N. Hortobagyi, M.D., F.A.C.P.

Abraxane (chemical name: albumin-bound or nab-paclitaxel) is a new formulation of paclitaxel, which is the active component of Taxol. There is a single head-to-head comparison of Abraxane and Taxol which suggests that we can give higher doses of Abraxane and that Abraxane is slightly more effective at those higher doses than a standard dose of Taxol. Whether this applies to inflammatory breast cancer or not is unknown. But clearly Abraxane is an effective drug, although whether the cost differential is justified in the case of an individual patient should be discussed with the treating oncologist.

The Ask-the-Expert Online Conference called Inflammatory Breast Cancer featured Gabriel Hortobagyi, M.D., Thomas Buchholz, M.D., and moderator Jennifer Sabol, M.D. answering your questions about inflammatory breast cancer, a rare but aggressive form of breast cancer.

Editor's Note: This conference took place in October 2006.

The materials presented in these conferences do not necessarily reflect the views of A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.

Fallappeal2016 popupad 300x125 1
Back to Top